Consolidated Statement of Shareholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-in Capital	Unearned ESOP Shares	Accumulated Other Comprehensive (Loss) Income	Retained Earnings
Beginning balance (in shares) at Dec. 31, 2017		121,875	16,548,829
Beginning balance at Dec. 31, 2017	$ 254,015	$ 40,987	$ 1,655	$ 168,412	$ (937)	$ (1,828)	$ 45,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(308)						(308)
Dividends on Series B and Series C preferred stock	(1,621)						(1,621)
Dividends on common stock	(330)						(330)
Restricted stock grant (in shares)			66,335
Restricted stock grant	0		$ 7	(7)
Restricted stock forfeitures (in shares)			(37,775)
Restricted stock forfeitures			$ (4)	4
ESOP shares released for allocation	61				61
Exercise of stock options (in shares)			42,505
Exercise of stock options	551		$ 4	547
ESOP compensation expense	20			20
Stock option and restricted stock compensation expense	(113)			(113)
Change in accumulated other comprehensive income	(3,572)
Change in accumulated other comprehensive income, including cumulative effect adjustment	(3,603)					(3,603)
Ending balance (in shares) at Jun. 30, 2018		121,875.000	16,619,894.000
Ending balance at Jun. 30, 2018	248,672	$ 40,987	$ 1,662	168,863	(876)	(5,400)	43,436
Beginning balance (in shares) at Mar. 31, 2018		121,875	16,621,811
Beginning balance at Mar. 31, 2018	250,837	$ 40,987	$ 1,662	168,765	(906)	(4,782)	45,111
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(669)						(669)
Dividends on Series B and Series C preferred stock	(810)						(810)
Dividends on common stock	(165)						(165)
Restricted stock grant (in shares)			14,057
Restricted stock grant	0		$ 2	(2)
Restricted stock forfeitures (in shares)			(25,400)
Restricted stock forfeitures			$ (3)	3
ESOP shares released for allocation	30				30
Exercise of stock options (in shares)			9,426
Exercise of stock options	122		$ 1	121
ESOP compensation expense	10			10
Stock option and restricted stock compensation expense	(34)			(34)
Change in accumulated other comprehensive income	(619)
Change in accumulated other comprehensive income, including cumulative effect adjustment	(649)					(649)
Ending balance (in shares) at Jun. 30, 2018		121,875.000	16,619,894.000
Ending balance at Jun. 30, 2018	248,672	$ 40,987	$ 1,662	168,863	$ (876)	(5,400)	43,436
Beginning balance (in shares) at Dec. 31, 2018		121,721	16,641,017
Beginning balance at Dec. 31, 2018	221,990	$ 40,972	$ 1,664	169,111		(4,035)	14,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,733)						(8,733)
Dividends on Series B and Series C preferred stock	(1,620)						(1,620)
Dividends on common stock	(333)						(333)
Restricted stock grant (in shares)			97,602
Restricted stock grant	0		$ 7	(7)
Restricted stock forfeitures (in shares)			(5,050)
Stock option and restricted stock compensation expense	43			43
Change in accumulated other comprehensive income	9,645					9,645
Ending balance (in shares) at Jun. 30, 2019		121,721.000	16,733,569.000
Ending balance at Jun. 30, 2019	220,992	$ 40,972	$ 1,671	169,147		5,610	3,592
Beginning balance (in shares) at Mar. 31, 2019		121,721	16,715,671
Beginning balance at Mar. 31, 2019	221,166	$ 40,972	$ 1,671	169,244		1,807	7,472
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,903)						(2,903)
Dividends on Series B and Series C preferred stock	(810)						(810)
Dividends on common stock	(167)						(167)
Restricted stock grant (in shares)			19,898
Restricted stock grant	0		$ 0	0
Restricted stock forfeitures (in shares)			(2,000)
Stock option and restricted stock compensation expense	(97)			(97)
Change in accumulated other comprehensive income	3,803					3,803
Ending balance (in shares) at Jun. 30, 2019		121,721.000	16,733,569.000
Ending balance at Jun. 30, 2019	$ 220,992	$ 40,972	$ 1,671	$ 169,147		$ 5,610	$ 3,592